Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.30 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2974168 | 0.87 | KDM4E (0.35) | HCAR3KCNH2MAPT | |
| SCHEMBL3417440 | 0.86 | NSD2 (0.39) | HCAR3VCAM1MAPTHTT | |
| SCHEMBL2969505 | 0.85 | VCAM1 (0.39) | HCAR3KCNH2VCAM1MAPTHTT | |
| SCHEMBL2976494 | 0.82 | HCAR3 (0.42) | HCAR3KCNH2HTT | |
| SCHEMBL13202988 | 0.81 | KCNH2 (0.37) | HCAR3KCNH2VCAM1MAPT | |
| SCHEMBL2977189 | 0.81 | ALDH1A1 (0.37) | KCNH2MAPTLMNATHRBNPSR1 | |
| SCHEMBL5675133 | 0.81 | — | — | |
| SCHEMBL3421976 | 0.80 | VCAM1 (0.35) | HCAR3KCNH2VCAM1MAPTHTT | |
| SCHEMBL2977431 | 0.79 | ALDH1A1 (0.34) | KCNH2 | |
| SCHEMBL3585555 | 0.78 | ALDH1A1 (0.36) | KCNH2LMNATHRBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121091-A1 | Processes of preparing asymmetric dinitrobenzamide mustard compounds, intermediate compounds useful therein and products obtained therefrom | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-05-13 | — | — | US | disclosed |
| EP-2059499-A1 | PROCESSES OF PREPARING ASYMMETRIC DINITROBENZAMIDE MUSTARD COMPOUNDS, INTERMEDIATE COMPOUNDS USEFUL THEREIN AND PRODUCTS OBTAINED THEREFROM | Auckland Uniservices Limited (NZ) | 2009-05-20 | — | — | EP | disclosed |
| WO-2008030112-A1 | PROCESSES OF PREPARING ASYMMETRIC DINITROBENZAMIDE MUSTARD COMPOUNDS, INTERMEDIATE COMPOUNDS USEFUL THEREIN AND PRODUCTS OBTAINED THEREFROM | AUCKLAND UNISERVICES LIMITED (NZ) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121091-A1 | Processes of preparing asymmetric dinitrobenzamide mustard compounds, intermediate compounds useful therein and products obtained therefrom | HRH2, HRH4, H1-2 | HCAR3 275/4885KCNH2 291/4885VCAM1 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.